Form 4: Charles River Labs Exec Trades Shares

Birgit Girshick, CEO of Charles River Laboratories, reported transactions involving the acquisition and disposition of company common stock.

Summary

• Birgit Girshick, Chief Executive Officer of Charles River Laboratories International, Inc., engaged in stock transactions on May 29, 2026, and May 30-31, 2026.
• On May 29, 2026, 9,961 shares of common stock were acquired at a price of $180.71 per share.
• Subsequent dispositions of common stock occurred on May 30, 2026 (1,204 shares) and May 31, 2026 (378 shares), also at a price of $180.71 per share.
• Following these transactions, Girshick beneficially owns 39,777 shares directly and 40,417 shares indirectly through a revocable trust.
• The filing also notes that unvested restricted stock units are scheduled to vest annually on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While there are stock transactions by the CEO, the nature of the acquisition and disposition at the same price suggests it's likely related to equity compensation or a pre-arranged plan, rather than a strong signal of positive or negative outlook.

Positives

• Acquisition of 9,961 shares by the CEO at a set price of $180.71, potentially indicating confidence in the stock.
• The CEO continues to hold a significant number of shares, both directly (39,777) and indirectly (40,417), suggesting continued investment in the company.

Negatives

• Disposition of 1,204 shares on May 30, 2026, and 378 shares on May 31, 2026, by the CEO.
• The transactions occurred at the same price as the acquisition, suggesting a potential pre-planned sale or hedging strategy rather than a market-driven sale.

Risks

• The filing does not explicitly mention any risks or future challenges.

Future Outlook

The filing indicates that unvested restricted stock units are scheduled to vest annually on May 29, 2027, May 29, 2028, May 29, 2029, and May 29, 2030.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for executive stock transactions. The reported price of $180.71 per share for both acquisition and disposition suggests these may be part of a pre-arranged trading plan (Rule 10b5-1) or related to equity compensation vesting, rather than opportunistic trading based on market sentiment.

Stakeholder Impact

• Shareholders: The transactions may be interpreted by some shareholders as a signal, though the context of equity compensation or a 10b5-1 plan limits definitive conclusions about the CEO's conviction.
• Employees: The vesting schedule of restricted stock units impacts future compensation for executives and potentially other employees.
• Management: The CEO's continued beneficial ownership, both direct and indirect, indicates ongoing commitment.

Next Steps

• Vesting of restricted stock units on May 29 of 2027, 2028, 2029, and 2030.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, SEC Filing, Insider Trading, Stock Transaction, CEO, Beneficial Ownership, Restricted Stock Units